---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-188277"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:31:00.686583+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition

## Summary
- Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
- Book-to-bill 1.02 for quarter; orders $157M; new modalities sales up 5% YoY.
- CEO Tony Hunt becomes Executive Chair; Olivier Loeillot appointed President & CEO effective Sept 1.
- Post-quarter-end, entered agreement to acquire chromatography innovator Tantti Laboratory Inc. (value undisclosed).
- FY 2024 revenue guidance narrowed to $620-635M; adjusted EPS guidance unchanged at $1.42-1.49.

## SEC filing metadata
- accession: 0001193125-24-188277
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312524188277/0001193125-24-188277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312524188277/d848995d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-188277
- JSON: https://secwatch.observer/filing/0001193125-24-188277.json
- Plain text: https://secwatch.observer/filing/0001193125-24-188277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.